; (2) gaps in data needed for full implementation of such subsection; (3) how the database established under subsection (a)(2) increases Federal visibility into the pharmaceutical supply chain; (4) how Federal agencies are able to use data analytics to conduct predictive modeling of anticipated drug shortages or national security threats; and (5) the extent to which industry has cooperated in mapping the pharmaceutical supply chain and building the database described in subsection (a)(2). (c) Confidential commercial information The exchange of information among the Secretary of Health and Human Services and the heads of other relevant agencies, including the Secretary of Defense and the Secretary of Homeland Security, for purposes of carrying out this section shall not be a violation of section 1905 of title 18, United States Code. (d) Clarification The database established under this section shall not be publicly disclosed. Nothing this subsection shall be construed to relieve the Secretary of Health and Human Services from its obligation to provide information to Congress.